Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Lymphoma, T-Cell, Peripheral 19Lymphoma, T-Cell, Cutaneous 18Lymphoma, T-Cell 17Lymphoma 16Lymphoma, Large B-Cell, Diffuse 9Leukemia, Lymphocytic, Chronic, B-Cell 9Mycosis Fungoides 8Lymphoma, Large-Cell, Anaplastic 8Multiple Myeloma 7Lymphoma, Non-Hodgkin 7Hodgkin Disease 7Lymphoma, Mantle-Cell 6Lymphoma, Follicular 6Lymphoma, B-Cell, Marginal Zone 5Immunoblastic Lymphadenopathy 5Burkitt Lymphoma 5Breast Neoplasms 5Waldenstrom Macroglobulinemia 4Sezary Syndrome 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasms 4Neoplasm Metastasis 4Leukemia, Myeloid, Acute 4Leukemia 4Urinary Bladder Neoplasms 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Lymphoma, Extranodal NK-T-Cell 3Lung Neoplasms 3Hematologic Neoplasms 3

Interventions

Capecitabine 4Temozolomide 3Octreotide 3Leucovorin 3Fluorouracil 3Everolimus 3vatalanib 2Trastuzumab 2Streptozocin 2Oxaliplatin 2Doxorubicin 2Bevacizumab 2tipifarnib 1romidepsin 1regorafenib 1pentetreotide 1motesanib diphosphate 1epothilone B 1batifiban 1Thalidomide 1Sorafenib 1Pantoprazole 1Omeprazole 1Irinotecan 1Interleukin-12 Subunit p35 1Interleukin-12 1High-Energy Shock Waves 1Gefitinib 1Floxuridine 1Fentanyl 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Gastrinoma × romidepsin × Clear all
NCT00084461 2013-06-04

Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Terminated
25 enrolled
Endocrine

Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡